GFAP Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB100-53809
Key Product Details
Species Reactivity
Validated:
Human, Mouse, Rat
Cited:
Human, Mouse, Rat
Predicted:
Canine (100%). Backed by our 100% Guarantee.
Applications
Validated:
Immunohistochemistry, Immunohistochemistry Free-Floating, Immunohistochemistry Whole-Mount, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Peptide ELISA, Western Blot
Cited:
Flow Cytometry, IF/IHC, Immunohistochemistry Free-Floating, Immunohistochemistry Whole-Mount, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
This GFAP Antibody was developed against a peptide with sequence C-DGEVIKESKQEHKD corresponding to C-Terminus according to NP_002046.1.
Reactivity Notes
Mouse reactivity reported in scientific literature (PMID: 30264465). Use in rat reported in scientific literature (PMID: 32581708).
Specificity
GFAP is thought to help to maintain astrocyte mechanical strength, as well as the shape of cells but its exact function remains poorly understood, despite the number of studies using it as a cell marker.
Marker
Astrocyte Marker
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Theoretical MW
50 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for GFAP Antibody
Western Blot: GFAP Antibody [NB100-53809]
Western Blot: GFAP Antibody [NB100-53809] - (0.005ug/ml) staining of Human Cerebellum (A) and (0.01ug/ml) Cerebral Cortex (B) (35ug protein in RIPA buffer). Detected by chemiluminescence.Western Blot: GFAP Antibody [NB100-53809]
Western Blot: GFAP Antibody [NB100-53809] - (0.1ug/ml) staining of Rat Brain lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.Applications for GFAP Antibody
Application
Recommended Usage
Peptide ELISA
Detection limit 1:32000
Western Blot
0.005 - 0.1ug/ml
Application Notes
Western blot: Approx 48kDa band observed in Human Cerebellum and Cerebral Cortex lysate and approx 50kDa in Rat Brain lysates and in preliminary testing of Mouse Cerebral Cortex lysate (calculated MW of 49.9kDa according to Human NP_002046.1 and Rat NP_058705.2).
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: GFAP
An increase in GFAP levels is often associated with neuroinflammation which results in the activation and proliferation of astroglia cell population (1,2). GFAP expression is also observed in brains of patients with neurodegenerative diseases including Alzheimer's and Parkinson's, epilepsy disorders, and brain injuries (1-4). Lesion sites associated with neurodegeneration can exhibit an array of gliosis characteristics from glial scarring with reduced astrocyte proliferation to activated, GFAP-positive astrocytes surrounding amyloid plaques (2). Furthermore, the GFAP gene is a target of single nucleotide polymorphisms in the coding region, considered a gain-of-function mutation, characterized by astrocytic inclusions, termed Rosenthal fibers, resulting in Alexander Disease (1-4). GFAP is also a center of many post-translational modifications, such as phosphorylation, which can alter various aspects of filament assembly (1,4).
References
1. Yang, Z., & Wang, K. K. (2015). Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends in Neurosciences. https://doi.org/10.1016/j.tins.2015.04.003
2. Hol, E. M., & Capetanaki, Y. (2017). Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin. Cold Spring Harbor Perspectives in Biology. https://doi.org/10.1101/cshperspect.a021642
3. Potokar, M., Morita, M., Wiche, G., & Jorgacevski, J. (2020). The Diversity of Intermediate Filaments in Astrocytes. Cells. https://doi.org/10.3390/cells9071604
4. Viedma-Poyatos, a., Pajares, M. A., & Perez-Sala, D. (2020). Type III intermediate filaments as targets and effectors of electrophiles and oxidants. Redox Biology. https://doi.org/10.1016/j.redox.2020.101582
Long Name
Glial Fibrillary Acidic Protein
Alternate Names
ALXDRD, FLJ45472, GFAP, GFAP astrocytes, glial fibrillary acidic protein
Gene Symbol
GFAP
UniProt
Additional GFAP Products
Product Documents for GFAP Antibody
Product Specific Notices for GFAP Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...